DM
JANX icon

Deerfield Management’s Janux Therapeutics JANX Stock Holding History

Deerfield Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-700,000
Closed -$17.5M – 146
2021
Q2 		$17.5M Buy
+700,000
New +$15.6M 0.31% 88

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Deerfield Management's JANX Position: Q3 2021 in Review

Deerfield Management sold out of Janux Therapeutics (JANX) in Q3 2021, closing a stake of 700,000 shares — an estimated $17.5M sold.

Deerfield Management first reported a position in JANX in Q2 2021 and held it in 1 quarter. The position peaked at $17.5M in Q2 2021. 45 funds tracked by Wall St. Rank hold JANX as of Q3 2021.

  • Deerfield Management reported no remaining Janux Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Deerfield Management sold 700,000 Janux Therapeutics shares in Q3 2021, an estimated $17.5M.
  • Deerfield Management first reported a position in Janux Therapeutics in Q2 2021 and held it in 1 quarter.
  • Deerfield Management's Janux Therapeutics position peaked at $17.5M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2021.

Based on Deerfield Management's 13F filing for Q3 2021, filed 15 Nov 2021.